305 related articles for article (PubMed ID: 9467349)
1. Oral pilocarpine HCl stimulates labial (minor) salivary gland flow in patients with Sjögren's syndrome.
Rhodus NL
Oral Dis; 1997 Jun; 3(2):93-8. PubMed ID: 9467349
[TBL] [Abstract][Full Text] [Related]
2. s-IgA and cytokine levels in whole saliva of Sjögren's syndrome patients before and after oral pilocarpine hydrochloride administration: a pilot study.
Rhodus N; Dahmer L; Lindemann K; Rudney J; Mathur A; Bereuter J
Clin Oral Investig; 1998 Dec; 2(4):191-6. PubMed ID: 10388393
[TBL] [Abstract][Full Text] [Related]
3. Effects of pilocarpine on salivary flow in patients with Sjögren's syndrome.
Rhodus NL; Schuh MJ
Oral Surg Oral Med Oral Pathol; 1991 Nov; 72(5):545-9. PubMed ID: 1745512
[TBL] [Abstract][Full Text] [Related]
4. The use of oral pilocarpine in xerostomia and Sjögren's syndrome.
Nusair S; Rubinow A
Semin Arthritis Rheum; 1999 Jun; 28(6):360-7. PubMed ID: 10406404
[TBL] [Abstract][Full Text] [Related]
5. Usefulness of basal and pilocarpine-stimulated salivary flow in primary Sjögren's syndrome. Correlation with clinical, immunological and histological features.
Rosas J; Ramos-Casals M; Ena J; García-Carrasco M; Verdu J; Cervera R; Font J; Caballero O; Ingelmo M; Pascual E
Rheumatology (Oxford); 2002 Jun; 41(6):670-5. PubMed ID: 12048294
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of unstimulated flow rates of whole and palatal saliva in healthy patients wearing complete dentures and in patients with Sjogren's syndrome.
Márton K; Boros I; Fejérdy P; Madléna M
J Prosthet Dent; 2004 Jun; 91(6):577-81. PubMed ID: 15211301
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of orally administered pilocarpine hydrochloride for patients with juvenile-onset Sjögren's syndrome.
Tomiita M; Takei S; Kuwada N; Nonaka Y; Saito K; Shimojo N; Kohno Y
Mod Rheumatol; 2010 Oct; 20(5):486-90. PubMed ID: 20517630
[TBL] [Abstract][Full Text] [Related]
8. Effect of Pilocarpine on impaired salivary secretion in patients with Sjögren's syndrome.
Jorkjend L; Bergenholtz A; Johansson AK; Johansson A
Swed Dent J; 2008; 32(2):49-56. PubMed ID: 18700333
[TBL] [Abstract][Full Text] [Related]
9. Use of muscarinic agonists in the treatment of Sjögren's syndrome.
Fox RI; Konttinen Y; Fisher A
Clin Immunol; 2001 Dec; 101(3):249-63. PubMed ID: 11726216
[TBL] [Abstract][Full Text] [Related]
10. Candida albicans levels in patients with Sjögren's syndrome before and after long-term use of pilocarpine hydrochloride: a pilot study.
Rhodus NL; Liljemark W; Bloomquist C; Bereuter J
Quintessence Int; 1998 Nov; 29(11):705-10. PubMed ID: 10200720
[TBL] [Abstract][Full Text] [Related]
11. Immunolocalization of AQP5 in resting and stimulated normal labial glands and in Sjögren's syndrome.
Gresz V; Horvath A; Gera I; Nielsen S; Zelles T
Oral Dis; 2015 Jan; 21(1):e114-20. PubMed ID: 24661359
[TBL] [Abstract][Full Text] [Related]
12. Efficacy prediction of cevimeline in patients with Sjögren's syndrome.
Yamada H; Nakagawa Y; Wakamatsu E; Sumida T; Yamachika S; Nomura Y; Mishima K; Saito I
Clin Rheumatol; 2007 Aug; 26(8):1320-7. PubMed ID: 17221146
[TBL] [Abstract][Full Text] [Related]
13. Salivary gland ultrasonography as a primary imaging tool for predicting efficacy of xerostomia treatment in patients with Sjögren's syndrome.
Takagi Y; Sumi M; Nakamura H; Sato S; Kawakami A; Nakamura T
Rheumatology (Oxford); 2016 Feb; 55(2):237-45. PubMed ID: 26338664
[TBL] [Abstract][Full Text] [Related]
14. A comparison of salivary gland hypofunction in primary and secondary Sjögren's syndrome.
Dawson LJ; Holt DJ; Higham SM; Longman LP; Field EA
Oral Dis; 2001 Jan; 7(1):28-30. PubMed ID: 11354918
[TBL] [Abstract][Full Text] [Related]
15. Elucidating the role of hyposalivation and autoimmunity in oral candidiasis.
Billings M; Dye BA; Iafolla T; Grisius M; Alevizos I
Oral Dis; 2017 Apr; 23(3):387-394. PubMed ID: 27998016
[TBL] [Abstract][Full Text] [Related]
16. Minor gland saliva flow rate and proteins in subjects with hyposalivation due to Sjogren's syndrome and radiation therapy.
Eliasson L; Almståhl A; Lingström P; Wikström M; Carlén A
Arch Oral Biol; 2005 Mar; 50(3):293-9. PubMed ID: 15740707
[TBL] [Abstract][Full Text] [Related]
17. Benefits of long-term pilocarpine due to increased muscarinic acetylcholine receptor 3 in salivary glands.
Minagi HO; Ikai K; Araie T; Sakai M; Sakai T
Biochem Biophys Res Commun; 2018 Sep; 503(2):1098-1102. PubMed ID: 29953856
[TBL] [Abstract][Full Text] [Related]
18. Cytokine concentrations in stimulated whole saliva among patients with primary Sjögren's syndrome, secondary Sjögren's syndrome, and patients with primary Sjögren's syndrome receiving varying doses of interferon for symptomatic treatment of the condition: a preliminary study.
Streckfus C; Bigler L; Navazesh M; Al-Hashimi I
Clin Oral Investig; 2001 Jun; 5(2):133-5. PubMed ID: 11480812
[TBL] [Abstract][Full Text] [Related]
19. [Effect of a gel-type denture adhesive on unstimulated whole saliva and minor salivary gland flow rates and on subjective orofacial sicca symptoms].
Demeter T; Houman AB; Gótai L; Károlyházy K; Kovács A; Márton K
Orv Hetil; 2018 Oct; 159(40):1637-1644. PubMed ID: 30277415
[TBL] [Abstract][Full Text] [Related]
20. Minor salivary glands function is decreased in hyposalivation-related diseases.
Wang Z; Li W; Hong X; Su JZ; Hua H; Peng X; Lv L; Yu GY
Arch Oral Biol; 2016 Sep; 69():63-70. PubMed ID: 27243418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
